Sexual Dysfunction
Study: Female sexual dysfunction drug market to grow 10% over next 5 years
Published in Women's Health Weekly, December 4th, 2003
According to the new Pharmacor study entitled "Female Sexual Dysfunction," the launch of drugs specifically approved for FSD will drive the market. Currently, no drugs are approved to treat the disease.
"Of all drugs in development for FSD, three transdermal testosterone formulations, Procter & Gamble's Intrinsa, Cellegy's Tostrelle, and BioSante's LibiGel, show the most promise," said David Lapidus, analyst at Decision Resources. "The launches of these drugs, starting with Intrinsa in 2004, will prompt a wave of marketing that will...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Coronary Heart Disease
Simple tests could signal and prevent heart disease in women - Osteoporosis
Habitual tea consumption has a minimal effect on fracture risk - Breast Cancer
PET imaging still questionable as means of predicting chemotherapy response - Infectious Disease
Bacterial infection in pregnancy Pap smears signals a risk for complications - Interstitial Cystitis
Researchers pinpoint possible cause of chronic bladder disease - Menopause
Study helps explain relationship between weight gain and female hormones - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
